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Abstract Papillary thyroid cancer (PTC) patients treated
with thyroidectomy and radioiodine remnant ablation (RRA)
often have detectable TSH-stimulated thyroglobulin (Tg)
levels without localizable disease after primary treatment.
To assess the value of repeat stimulated Tg assays in these
patients’ follow-up, we retrospectively analyzed 86 cases
followed in 5 Italian thyroid-cancer referral centers. We
enrolled 86 patients with PTCs treated with total/near-total
thyroidectomy plus RRA between January 1,1990 and Jan-
uary 31, 2006. In all cases, the initial postoperative visit
revealed stimulated serum Tg C1 ng/mL, negative Tg anti-
bodies, and no structural evidence of disease. None received
empiric radioiodine therapy. Follow-up (median: 9.6 years)
included neck ultrasound and basal Tg assays (yearly) and at
least 1 repeat stimulated Tg assay. Of the 86 patients ana-
lyzed (initial risk: low 63 %, intermediate 35 %, high 2 %),
one (1 %) had ultrasound-detected lymph node disease and
persistently elevated stimulated Tg levels at 3 years. In 17
(20 %), imaging findings were consistently negative, but the
final stimulated Tg levels was still [1 ng/mL (median
2.07 ng/mL, range 1.02–4.7). The other 68 (80 %) appeared
disease-free (persistently negative imaging findings with
stimulated Tg levels B1 ng/mL). Mean intervals between
first and final stimulated Tg assays were similar (5.2 and
4.8 years) in subgroups with versus without Tg normaliza-
tion. Reclassification as disease-free was significantly more
common when initial stimulated Tg levels were indetermi-
nate (\10 ng/mL). In unselected PTC cohorts with incom-
plete/indeterminate biochemical responses to thyroidectomy
and RRA, periodic remeasurement of stimulated Tg allows
most patients to be classified as disease-free.
Keywords Papillary thyroid cancer  Thyroglobulin 
Biochemical incomplete response  Indeterminate
response  Follow-up  Recurrences
Introduction
The incidence of papillary thyroid cancers (PTC) has tri-
pled since the mid-1970s [1], but outcomes are good in the
vast majority of cases (approximately 98 % according to
the Surveillance, Epidemiology, and End Results Program
Database). Nevertheless, life-long surveillance is still the
rule in many centers because disease recurrence has been
observed as late as 40 years after the diagnosis [2, 3].
The cornerstones of the surveillance process are the neck
ultrasound examination and assays of serum levels of
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thyroglobulin (Tg), which is produced exclusively by fol-
licular thyrocytes. The serum Tg assay is a widely available,
low-cost procedure with high sensitivity and specificity for
detecting persistent or recurrent thyroid cancer [4]. How-
ever, detectable Tg levels may reflect the residual presence
of normal thyrocytes and/or the persistence or recurrence of
neoplastic thyroid tissue. This diminishes the specificity of
the marker, particularly in the growing population of PTC
patients who do not undergo postoperative radioiodine
remnant ablation (RRA) [5]. However, Tg assay positivity
(without structural evidence of disease) is also reported in up
to 36 % of the PTC patients who do undergo ablation [6–10].
As for sensitivity, serum Tg assays may also fail to identify
small volumes of neoplastic thyroid tissue, especially when
they are performed during thyroid hormone suppression of
thyroid-stimulating hormone (TSH). Measurement of TSH-
stimulated levels of Tg is thus recommended to maximize
sensitivity [4]. This approach is complicated by the fact that
withdrawal of thyroid hormone replacement therapy—the
method traditionally used to increase TSH levels—subjects
patients to the unpleasant symptoms of hypothyroidism for
approximately 3–6 weeks [11]. This problem can now be
avoided with the use of recombinant human TSH (rhTSH)
[12], although the gain in tolerability is offset to some extent
by a non-negligible cost increase related to the price of the
drug.
These considerations justify attempts to rationalize the
use of stimulated Tg testing during follow-up of patients with
PTCs. Repetition of these assays is of little benefit once the
patient meets the criteria for classification as disease-free
[13–16]. For those treated with total/near-total thyroidec-
tomy followed by RRA, this means the absence of clinical
and imaging evidence of tumor [i.e., neck US and/or diag-
nostic 131I whole-body scan (dxWBS)] and basal and stim-
ulated Tg levels that are B1 ng/mL, in the absence of
thyroglobulin antibodies (TgAb) [4]. The negative predic-
tive value of all of these findings is almost 100 % [17–21].
Clinical or imaging (cross-sectional or functional) findings
compatible with persistent macroscopic disease usually
prompt additional treatment or at least a more active form of
surveillance [4]. There is no consensus, however, regarding
the management of individuals with detectable Tg levels in
the absence of localizable disease, and the benefit from
repeating TSH-stimulated testing in this patient population is
uncertain. Reported outcomes in these cases vary widely,
with imaging-documented evidence of disease emerging in
8–50 % of patients. In similar percentages (13–50 %),
however, the Tg level reportedly diminishes progressively
and at some point becomes undetectable, thereby allowing
the patient to be classified as disease-free [6–10].
The goals of the present study were (1) to shed light on
the natural course of PTC associated with detectable stim-
ulated Tg levels in the absence of localizable disease as the
best response at the initial post-treatment assessment and
(2) to assess the value of repeated assay of TSH-stimulated
Tg levels in the follow-up of these patients.
Patients and methods
Study design and setting
This retrospective, observational study was conducted with
institutional review board approval in 8 hospital-based pri-
mary thyroid cancer referral centers in Italy (2 nuclear med-
icine units, 6 thyroid disease units). Since 1990, these centers
have used similar protocols for the postoperative follow-up of
patients with PTC. For those who undergo total or near-total
thyroidectomy with RRA (the focus of the present study), the
first follow-up visit is scheduled 6–18 months after the initial
treatment. It includes assays of basal and TSH-stimulated
serum Tg levels (with simultaneous assessment of TgAb
levels) [22] and neck ultrasound studies performed with
multifrequency probes (7.5–12 MHz) by an experienced staff
endocrinologist. In the past, dxWBS was also performed
routinely during the first visit in some centers, but since 2006
this procedure has been used only as a second-line study [23].
Subsequent visits are scheduled yearly and include basal Tg
assay, TgAb levels, and neck ultrasound. If the stimulated Tg
assay is positive at the initial visit, it is repeated periodically
(frequency at the discretion of the physician) as long as levels
remain in the detectable range. Additional functional and/or
cross-sectional imaging studies are ordered as needed. If
suspicious lymph nodes are found and are eligible for surgical
removal, fine needle aspiration biopsy is performed for
cytology, measurement of Tg levels in the needle washout
fluid and, since 1997, high-sensitivity assay of washout fluid
for Tg and TSH receptor mRNA [24, 25]. All Tg and TgAb
assays are done in the center’s own laboratory. Between 1991
and 2006, a number of Tg assays with functional sensitivities
of 1 ng/mL were used in the participating centers. Between
2002 and 2005, all centers that enrolled patients began using
immunometric serum Tg assays with a functional sensitivity
of 0.1–0.2 ng/mL. As for TgAb, all assays used on study
patients were immunometric or radioimmunometric with
institutional cut-offs that varied from center to center.
Cohort selection
We reviewed the thyroid cancer databases of each partic-
ipating center and identified patients consecutively diag-
nosed with PTC between January 1, 1990 and January 31,
2006 who met all the following eligibility criteria: (1)
primary treatment consisting of total or near-total thy-
roidectomy followed by RRA; (2) surgical pathology report
confirming diagnosis of PTC; (3) all diagnostic procedures
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during follow-up carried out by the staff of the participat-
ing study center; (4) all serum Tg values measured with
assays with a functional sensitivity of 1 ng/mL or less and
accompanied by negative Tg antibody assay results; (5)
complete findings for each year of follow-up (in accor-
dance with the protocol described above). From this set of
patients, we then selected those with (1) a stimulated serum
Tg level of [1 ng/mL and negative clinical or imaging
findings at the first postoperative visit and (2) at least one
other stimulated Tg assay performed B10 years after the
first. To focus on the natural history of these tumors during
follow-up, we then excluded from our analysis any cohort
members who had received further therapy after the pri-
mary treatment.
Data collection and end points
Data on cohort patients were collected from the medical
records and stored in an electronic database. They included
demographics, data on the primary treatment (surgery and
RRA), tumor characteristics, documentation of structural
disease during the follow-up period, and any additional
treatments that were performed. The prespecified primary
endpoint was the spontaneous decline of the stimulated Tg
level to B1 ng/mL in the presence of persistently negative
findings on neck ultrasound and on any other imaging
studies that may have been performed (i.e., the criteria for
classification as disease-free established by the American
Thyroid Association) [4]. The secondary endpoints were
assessed at the end of follow-up and included (1) the per-
sistence of stimulated Tg levels [1 ng/mL and (2) the
emergence of clinical/imaging evidence of disease.
Statistical analysis
Differences between categorical variables (expressed as
numbers and percentages) were evaluated with the Chi-
square test or the Fischer Exact test for small samples;
differences between continuous variables (reported as
medians and ranges) were assessed with the Mann–Whit-
ney test. A P value \0.05 was considered statistically
significant. Stat view 5.0.1 software (SAS Institute inc.,
Cary, NC) was used for all statistical analyses.
Results
As shown in Fig. 1, of the 365 patients who met the eli-
gibility criteria, 93 (26 %) had TSH-stimulated serum Tg
levels[1 ng/mL with no structural evidence of disease at
Fig. 1 Study cohort selection procedure and follow-up findings. A
total of 365 cases of PTC satisfied the initial criteria for inclusion in
this study. At the first postoperative visit [6–18 months after
radioiodine remnant ablation (RRA)], 93 of these individuals were
Tg-POS/Imaging-NEG. After exclusion of the 7 who received
additional radioiodine therapy, the study cohort contained 86 patients.
Tg-NEG stimulated serum Tg levels B1 ng/mL, Tg-POS stimulated
serum Tg levels [1 ng/mL, Imaging-NEG no suspicious findings
whatsoever on neck ultrasound or any other imaging studies that were
performed, Imaging-POS suspicious/indeterminate findings on neck
ultrasound. In all cases reported as Imaging-POS, the presence of
structural disease was subsequently confirmed by biopsy and/or
surgical pathology. The follow-up durations (from first to final post-
treatment assessment) for this cohort ranged from 3.5 to 19.5 years
(median 8.2 years)
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the first (1-year) postoperative assessment and at least one
other stimulated Tg assay during follow-up. The 7 patients
in this group who received additional radioiodine therapy
were excluded from further analysis, leaving a study cohort
of 86 patients being followed in 5 of the 8 centers. Their
baseline characteristics are summarized in Table 1.
The final stimulated serum Tg assay in the study cohort
was performed 1–10 years after the first (median:
5.1 years). TSH stimulation was achieved with LT4 with-
drawal in 34 cases and the administration of rhTSH in the
other 52 cases. In 42 (49 %) cases, the same stimulation
method was used for the first and final Tg assays (LT4
withdrawal in 34 cases, rhTSH injection in 8) (see
Table 1). In the remaining 44 (51 %), the initial assay had
been done after LT4 withdrawal and the final assay after
rhTSH administration (see Table 1). At this point (Fig. 1),
68 (80 %) of the 86 patients presented stimulated (and
basal) Tg levels that were B1 ng/mL together with per-
sistently negative findings on physical examination, neck
ultrasound, and any other imaging studies performed. In
accordance with ATA Guidelines [4], these patients were
thus reclassified as apparently disease-free, and monitoring
of stimulated Tg levels was discontinued. In 17 other cases
(19 %), the physical examination and neck ultrasound
study were still negative, but the stimulated Tg levels
remained above the 1 ng/mL cut-off (median 2.07 ng/mL,
Table 1 Baseline
characteristics of the study
cohort
Patient characteristics Study cohort (n = 86)
Referral center—n (%)
Center 1 42 (49)
Center 2 36 (42)
Center 3 6 (7)
Center 4 1 (1)
Center 5 1 (1)
Age (years)—median (range) 43.9 (15–87)
Females—no. (%) 66 (78)
Tumor size (mm)—median (range) 19 (2–60)
Multifocal tumors—no. (%) 35 (41)
Extrathyroidal extension—no. (%)
None 61 (71)
Microscopic (T3) 24 (28)
Macroscopic (T4) 1 (1)
Lymph node metastases—no. (%) 19 (21)
Distant metastases—no. (%) 1 (1)
131I ablation dose activity (mCi)—median (range) 66 (15–145)
ATA risk class—no. (%)
Low 54 (63)
Intermediate 30 (35)
High 2 (2)
Initial postoperative findings (1 year)
Serum Tg levels—median (range)
Basal 0.71 (0.01–2.8)
Stimulateda 2.1 (1.05–27.9)
Post-treatment WBSb
No uptake observed 56 (66)
Uptake confined to thyroid bed 29 (34)
Uptake outside the thyroid bed –
Characteristics are those documented at the time of initial treatment (total thyroidectomy ? radioiodine
remnant ablation) with the exception of serum thyroglobulin levels, which are those measured at the first
follow-up visit (6–18 months after initial treatment)
ATA American Thyroid Association, mCi millicurie, Tg thyroglobulin, TSH thyroid-stimulating hormone
a Assay performed according to standardized protocols (ATA 2009) after thyroid hormone withdrawal in
78 cases and after rhTSH injection in 8
b Data available for 85/86 patients
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range 1.02–4.7). (In all but 2 of the 17 (12 %), the basal Tg
assay was negative (i.e., B1 ng/mL.) The mean interval
between the first and last stimulated Tg assays in this group
was not significantly different from that of the group with
assay negativization (4.8 vs. 5.2 years, Mann–Whitney
test, P = 0.71).
As for the final patient in the study cohort (Fig. 1), he
had undergone total thyroidectomy, central neck dissec-
tion, and RRA (activity 106 mCi) at age 20 for an inter-
mediate-risk (pT3, pN1a) PTC. The first postoperative
assessment had revealed an rhTSH-stimulated Tg level of
1.05 ng/mL with negative findings on both neck ultrasound
and dxWBS. Three years later, the rhTSH-stimulated Tg
level was reassessed and found to be 1.24 ng/mL. (Basal
Tg levels were undetectable at the time of both stimulation
tests.) Suspicious lymph nodes were noted on neck US and
cytologically confirmed to be PTC metastases. After dis-
cussion of the pros and cons of a second operation, the
patient opted for active surveillance instead. In the
2.5 years that have passed since that time (5.6 years since
the initial treatment), neck ultrasound studies performed at
intervals of 6–12 months have revealed no change what-
soever in the size or appearance of lymph node lesions. At
the final follow-up visit [median 8.2 years (range
3.5–19.5 years) after the first assessment, 9.6 years (range
4–21 years) after diagnosis], this patient was still the only
one in the study cohort with documented evidence of
structural recurrence.
As shown in Table 2, the likelihood of being reclassified
as disease-free during follow-up in the 78 patients whose
initial stimulated Tg levels were \10 ng/mL (i.e., those
falling into the indeterminate range) was significantly
greater than that of the 8 patients with higher Tg levels
(i.e., biochemical incomplete responses) [26]. It was not
significantly related to the initial American Thyroid
Association (ATA) risk class or to the radioiodine dose
used for remnant ablation. The sensitivity and predictive
values of stimulated Tg in identifying patients destined to
develop localizable disease are reported in Table 3.
Discussion
In this retrospective, multicenter study, we investigated the
natural course of PTC in 86 patients whose initial assess-
ment after primary treatment (total thyroidectomy ? RRA)
revealed TSH-stimulated serum Tg levels[1 ng/mL in the
absence of localizable disease. This definition included
patients whose biochemical response to therapy would
currently be classified as incomplete (stimulated Tg levels
C10 ng/mL) or indeterminate (stimulated levels [1 and
\10 ng/mL) [26].
In 80 % of the cases, repetition of the stimulated Tg assay
at some point during follow-up (median: 5.2 years after the
initial assay) revealed levels below 1 ng/mL, while imaging
findings remained persistently negative, thereby allowing
these patients to be reclassified as disease-free, as defined by
the 2009 ATA Guidelines [4]. In the remaining 20 %, the
most recent stimulated serum Tg level recorded (median
4.8 years after the first assay) was still above 1 ng/mL,
Table 2 Baseline patient
characteristics associated with
negativization of TSH-
stimulated Tg assay during
follow-up
Patient characteristicsa Last TSH-Stimulated Tg assay resultb P value
Tg-NEG (n = 68) Tg-POS (n = 18)
Initial postoperative TSH-stimulated Tg level—no. (%)
[1 and\10 ng/mL 65 (95.6) 13 (72.2) 0.006
C10 ng/ml 3 (4.4) 5 (27.8)
ATA risk class—no. (%)
Low 44 (64.7) 10 (55.6) 0.52
Intermediate 22 (32.3) 8 (44.4)
High 2 (3) 0 (0)
131I ablation dose activity (mCi)—median (range) 67.3 (15–145) 63.3 (15–106) 0.9
Tg thyroglobulin, TSH thyroid-stimulating hormone, ATA American Thyroid Association, mCi millicurie
a See Table 1
b Tg-NEG (B1 ng/mL); Tg-POS ([1 ng/mL)
Table 3 Sensitivity, specificity, and predictive values of stimulated Tg at the time of last stimulation test
Sensitivity Specificity NPV PPV
Stimulated Tg at last stimulation test 100 % 80 % 100 % 6 %
Tg thyroglobulin, NPV negative predictive value, PPV positive predictive value
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although only 1 of these patients had developed structural
evidence of disease. These outcomes were unchanged at the
final follow-up visit (median 8.2 years after the initial
assessment, range: 3.5–19.5 years): no evidence of struc-
tural disease had emerged in any of the patients reclassified
as disease-free or in the 17 whose stimulated Tg levels
remained[1 ng/mL in the absence of localizable disease.
Several other retrospective studies have explored the
significance of detectable Tg production in the absence of
localizable disease. Reported outcomes in PTC patient
populations with these characteristics vary widely [6–10]
depending on the cut-off used to define detectable Tg
production and the specific features of the study cohort
(including tumor characteristics, initial risk of recurrence,
the use of additional radioiodine treatment, duration of
follow-up). Yim et al. [9], for example, retrospectively
analyzed 186 cases of differentiated thyroid cancer (DTC)
with stimulated Tg levels C2 ng/mL roughly 1 year after
thyroidectomy and RRA. Repeat stimulated Tg assays
during follow-up (i.e., 1–2 years after the first assay)
allowed 45 (24 %) of these patients to be reclassified as
disease-free. A similar picture emerged from the retro-
spective study by Pitoia et al. [10]. They examined a
smaller cohort of 32 patients whose only anomaly at the
first follow-up visit was a stimulated Tg level of[1 ng/mL.
Six (19 %) were subsequently reclassified as disease-free
on the basis of negative results in the repeat stimulated Tg
assay. In all 6 cases, the initial stimulated Tg level had
been B1.9 ng/mL, and assay negativization occurred
within 2.5 years.
These figures are in stark contrast with the 80 % rate of
patients who became disease-free during our follow-up.
The results will obviously be influenced by several factors
including: the type ad completeness of primary treatment,
the use of second-line imaging studies, and the Tg
threshold used for study enrolment. In fact, the threshold
used by Yim et al. [9] was twice as high as the one we
chose. Compared with the patients in our cohort, many of
those included in their study probably had more markedly
abnormal stimulated Tg, which is also predictive of
structural recurrence [26]. However, the high disease-free
rates that emerged during our follow-up are probably
related mainly to the clinical profiles of our cohort. Almost
two-thirds of our patients were initially classified as low
risk, as opposed to less than 40 % of the cohort examined
by Pitoia et al. [10]. In addition, the proportion of their
cases that were considered high risk was 7 times that of our
cohort (15 vs. 2 %). Similar considerations apply to the
patients analyzed by Yim et al. [9], 155 (83 %) of whom
had lymph node metastases at diagnosis [vs. 19 (21 %) in
our study].
Although retrospective studies like these are bound to
vary in terms of cohort characteristics, it is important to
note that the risk category distribution of the patients in our
cohort (Table 1) is much more consistent with those
reported in large unselected series of DTC patients [3, 27,
28]. It is also compatible with figures from the SEER
Program database, which show that almost 68 % of thyroid
cancers are confined to the thyroid gland at diagnosis (and
are therefore considered at low risk for recurrence
according to the ATA risk stratification system), while 26
and 4 % spread to regional lymph nodes and distant sites,
respectively [29].
This distinction is important because the utility of
repeating stimulated serum Tg assays in patients with
suspicious findings that are exclusively biochemical is
related mainly to its ability to identify patients who have
been cured rather than those with persistent or recurrent
cancer. Indeed, while the negative predictive value of TSH-
stimulated Tg assay approaches 100 %, the positive pre-
dictive value is dismally low (26 %) [30]. In our study, the
negative predictive value of stimulated Tg was 100 %
while the positive predictive value was only 6 %. Patients
who meet the criteria for classification as disease-free/ex-
cellent response have a minimal risk of recurrence, esti-
mated at 1–2 % [31, 32]. They can thus be followed with
more relaxed protocols, which offer important potential
advantages in terms of patient stress and health-care
spending. While the results of the studies cited above
indicate that only a minority of patients with exclusively
biochemical abnormalities stand to benefit by this down-
grading of risk, our experience indicates that in a more or
less typical cohort of patients with PTC, in which low-risk
predominates, repetition of the stimulated Tg assay can
markedly reduce the number of patients who actually
require close, more costly follow-ups.
In our cohort, negativization of the stimulated Tg assay
during follow-up displayed no significant association with
the initial ATA risk class or the radioiodine dose used for
remnant ablation. However, it was significantly more
common in the subgroup whose initial stimulated Tg value
was [1 ng/mL but \10 ng/mL (i.e., within the so-called
indeterminate range) than that in the subgroup with initial
values that met the criteria for an incomplete biochemical
response. This finding is consistent with the results repor-
ted by Pitoia et al. [10]. In their study, all cases of assay
negativization occurred in patients whose initial levels
were between 1.5 and 1.9 ng/mL. Yim et al. also observed
that rates of negativization declined as the initial stimulated
Tg level rose [9].
As in the study by Yim, to observe the natural history of
patients with detectable Tg levels but no imaging evidence
of disease, we chose to exclude the 7 patients that received
additional courses of radioiodine treatment. As for the
outcome of these 7 patients excluded from the analysis,
only one developed evidence of disease on imaging during
472 Endocrine (2016) 54:467–475
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follow-up, while 3 patients were finally classified as free
from disease.
The main limitations of our study are related to its retro-
spective, multicenter design. Because the cohort was com-
posed of patients diagnosed over a period of 16 years in 5
different centers, baseline stimulated Tg levels were mea-
sured with several different assays. The fact that all assays
used in this cohort had functional sensitivities of 1 ng/mL or
less (inclusion criterion) allowed us to retrospectively
dichotomize the results as detectable/undetectable using the
evidence-based cut-off value recommended by the ATA [4].
The use of a categorical rather than continuous variable to
express Tg levels precluded quantitative analysis of the
changes in stimulated Tg over time, but our findings clearly
confirm the validity of this cut-off for predicting recurrence.
The same cut-off was used regardless of whether Tg was
assayed after LT4 withdrawal or rhTSH injection, a practice
that is fully consistent with recommendations of the ATA [4]
and widely used in clinical settings, where the administration
of exogenous TSH is gradually replacing thyroid hormone
withdrawal. Several groups, however, have shown that Tg
levels measured during hormone withdrawal are significantly
higher than those observed under rhTSH stimulation [33, 34].
These findings suggest that in the 44 patients in our cohort
whose initial and final Tg assays were performed after LT4
withdrawal and rhTSH stimulation, respectively, some cases
of assay normalization might be related to the lower intensity
TSH stimulation used in the second assay. False negativity of
this type is in our opinion unlikely. First of all, while Tg
measured after LT4-withdrawal consistently exceeds that
observed in the same patient under rhTSH stimulation, this
difference rarely (7 % of cases) results in discordant classi-
fication of the two specimens as positive/negative using the
1 ng/mL cut-off [33]. Second, in our cohort, the stimulated Tg
negativation rate in this subgroup whose assays were per-
formed under different types of stimulation (36/44, 82 %) is
almost identical to that observed in the cohort as a whole (68/
86, 80 %). For these reasons, the high proportion of patients
reclassified as disease-free in our study is probably a reliable
estimate.
The median interval between the first and final stimulated
Tg assays in our cohort was 5.1 years, and the patients
identified as disease-free at this point remained persistently
negative in imaging studies during the remainder of follow-up
(median 9.6 years). It is impossible to draw any definite
conclusions on the optimal timing of repeat stimulated Tg
assays on the basis of our findings. Nonetheless, from a cost–
benefit viewpoint, the 5-year follow-up visit appears to be a
reasonable choice. First, our previous experience shows that
the vast majority of disease recurrences are detected within
this time frame [3]. However, as noted earlier, the goal of re-
testing is not to detect recurrence but to identify patients who
can be considered disease-free (i.e., patients whose previously
positive assay results probably reflected the presence of nor-
mal thyroid tissue remnants or even small nests of neoplastic
cells that are still viable but destined to succumb with time to
the effects of the initial treatment). In this context, it is
interesting to note that in populations not subjected to RRA,
basal Tg production declines spontaneously, and by year 5,
80 % of these patients have undetectable levels [5, 35]. In
general, then, earlier re-testing is likely to be associated with
lower rates of assay normalization. The intervals between the
first and final stimulated Tg assays in our cohort varied
widely, but it is important to note that the median length was
not significantly different between patients with Tg nega-
tivization and patients with Tg[1 ng/mL at last assessment.
In all probability, the increasing use of more sensitive Tg
assays will eventually eliminate the need to assess Tg pro-
duction under TSH stimulation, and the cost of assessing
serum Tg to identify patients who are disease-free will be
substantially reduced. However, a validated cut-off level that
optimally identifies these patients is still not available for
these new assays [30, 36–38].
In conclusion, up to one-third of PTC patients treated
with thyroidectomy and RRA will have detectable stimu-
lated Tg levels with no structural evidence of disease at
1 year. Our findings show that, in cases that fall within this
‘‘diagnostic gray zone,’’ continued monitoring of stimu-
lated Tg levels should be considered a key component of
follow-up, not because of its capacity to identify patients
with persistent/recurrent disease, which is in fact limited,
but because it allows the confident exclusion of this out-
come in a substantial proportion of this population.
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